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Published by Elsevier Inc. doi:10.1016/j.jacc.2011.01.020Many interesting and important reports were published in
the past year (roughly July 2009 through June 2010) in the
fields of epidemiology, health services research, and out-
comes research. We have chosen a few of the highlights to
discuss here, necessarily leaving aside some excellent work.
Secular Trends in Cardiovascular Outcomes
The rise of ischemic heart disease during the first half of the
20th century was followed by a progressive decline in the
second half of the century. Several recent reports now
document that this decline has continued into the first
decade of the 21st century. Trends in the incidence of acute
myocardial infarction (MI) might be affected by the adop-
tion of more sensitive biomarkers (troponins) as the diag-
nostic standard. In Olmsted County, Minnesota, the use of
troponin as a diagnostic test minimally affected the inci-
dence of ST-segment elevation myocardial infarction
(STEMI) between 1987 and 2006 but increased by 43% the
incidence of non-STEMI (1). In Kaiser Permanente of
Northern California, the incidence of MI declined between
1999 and 2008: the rate of STEMI declined progressively
by 62%, and the rate of non-STEMI declined after an initial
bump upward because of the adoption of troponin I testing
(2). The rate of MI in Medicare beneficiaries declined 6%
per year between 2002 and 2007 (3), and the same trend was
documented in Ontario, Canada, in association with re-
duced population levels of cholesterol and systolic blood
pressure (4). Improvements in risk factor control appear to
be responsible for most of these declines in coronary disease,
in part because of more widespread drug treatment and in
part because of public health programs. Reduced population
rates of smoking have likely contributed to this decline in
coronary disease; smoking bans in public places were found
to reduce the rate of MI at the community level in 2 separate
studies (5,6). Population-level interventions to reduce so-
dium intake might further decrease cardiovascular events
substantially, according to 2 independent policy models
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and several food processing companies. Finally, although
treatment of out-of-hospital cardiac arrest plays a relatively
smaller role at the population level in reducing heart disease
mortality, greater use of public access defibrillation appears
to have improved survival in Japan (9) and in 10 commu-
nities in the United States and Canada (10). Placement of
automated external defibrillators in strategic locations, such
as train stations and crowded public areas, appears to be a
cost-effective approach to their use (11).
Risk Prediction
The Framingham risk score and related cardiovascular risk
prediction instruments (12) use relatively simple clinical
descriptors (age, sex, blood pressure, cholesterol levels,
smoking status, diabetes) to estimate a subject’s risk for
developing cardiovascular disease over the next 5 to 10 years,
or over his or her remaining lifetime (13). Although these
scores are useful, they are also limited in a number of ways,
and investigators continue to propose improvements, typi-
cally by adding new risk markers. There is now reasonable
scientific consensus on how to evaluate “new and improved”
risk scores (14), but Tzoulaki et al. (15) found that most
studies that claimed to have improved on the Framingham
risk score were flawed in their designs, their analyses, or
both. Nevertheless, many reports continue to appear pro-
posing the use of novel risk markers.
The potential value of lipoprotein(a) (Lp[a]) in predicting
cardiovascular risk was examined in detail by the Emerging
Risk Factors Collaboration, a remarkable cooperative project to
analyze individual participant data from 36 prospective epide-
miologic studies (16). Analysis of data from 126,643 subjects
showed a curvilinear relationship between increasing Lp(a)
levels and increased cardiovascular risk, independent of con-
ventional risk factors. This elegant analysis did not, however,
report whether the use of Lp(a) increased risk discrimination or
risk reclassification, 2 measures of the practical value of a risk
marker. Several polymorphisms in the Lp(a) gene were shown
to be associated with both Lp(a) levels and the risk for coronary
disease (17).
B-type natriuretic peptide (BNP) has also been proposed as
a risk marker for the development of cardiovascular disease in
healthy subjects. A meta-analysis of 40 prospective studies,
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levels were associated with the risk for future cardiovascular
events (MI, stroke, and heart failure) (18). A prospective
study of 8,383 subjects in the Netherlands reported that
N-terminal pro-BNP predicted cardiovascular events over
7.5 years of follow-up (19), independent of other risk
factors. N-terminal pro-BNP levels did not, however, sig-
nificantly improve risk discrimination, as measured by the
c-index (0.838 to 0.841).
The Emerging Risk Factor Collaboration examined the
independent value of C-reactive protein (CRP) as a risk
predictor among 160,309 subjects from 54 prospective
studies (20). CRP levels were independently predictive of
coronary heart disease and of stroke in their analysis but were
also significantly associated with noncardiovascular deaths,
including cancer, respiratory disease, and even traumatic death,
a curious observation that is largely unexplained.
The idea of using a panel of general biomarkers to
improve risk prediction was supported by several recent
studies. The MORGAM (MONICA, Risk, Genetics, Ar-
chiving, and Monograph) Biomarker Project developed a
multimarker risk score (CRP, N-terminal pro-BNP, and
troponin I) in 1 population, which they validated in an
independent population, and showed the score significantly
improved the c-index (from 0.67 to 0.70, p  0.0035) and
modestly improved risk reclassification (21). A similar study
in a cohort from Malmö, Sweden, suggested that CRP and
N-terminal pro-BNP were associated with cardiovascular
events, with an improved c-statistic but without improve-
ment in risk reclassification (22).
Evidence for subclinical atherosclerosis is an intriguing
risk marker because it is plausibly a “downstream” predictor
of future coronary events compared with biomarkers or
genetic markers. An ARIC (Atherosclerosis Risk in Com-
munities) study of 13,145 subjects found that carotid
intima-media thickness improved prognostic prediction sig-
nificantly and reclassified the risk levels in 23% of subjects
(23). A MESA (Multi-Ethnic Study of Atherosclerosis)
study of 6,814 subjects found that coronary calcium score
added significant prognostic information to that provided by
conventional risk markers; in particular, the calcium score
improved risk reclassification significantly, especially in
subjects who were at intermediate Framingham risk (24).
The MESA investigators also found that subjects with
higher calcium scores were more likely to be prescribed
medications to lower lipid levels and blood pressure and
were more likely to begin aspirin treatment (25). In another
cohort, however, subjects with high coronary calcium scores
were much more likely to undergo myocardial perfusion
imaging, stress echocardiography, or computed tomo-
graphic (CT) coronary angiography in the subsequent 6
months, with 40% of those with scores between 400 and
999 being tested and 55% of those with scores of 1,000 or
more being tested (26).
The flip side of a high calcium score is a zero calcium
score, which was associated with especially low cardiovas-cular risk in several studies. Only 5 of 422 subjects (1.2%)
with no coronary calcium at entry developed measureable
coronary calcium over 2 years, 26 (6.2%) at 4 years, and 49
(11.6%) at 5 years in 1 follow-up study (27); the investiga-
tors suggested that the “warranty period” for a normal
calcium score was no more than 4 years. In the MESA
study, there were only 10 “hard cardiac events” (0.3%)
among 3,415 asymptomatic subjects with zero calcium
scores over a median of 49 months of follow-up (28). It is
important to note that a zero calcium score does not exclude
obstructive coronary disease among symptomatic patients:
16 of 72 patients (22%) in the CORE 64 (Coronary
Evaluation Using Multidetector Spiral Computed Tomog-
raphy Angiography Using 64 Detectors) study had signifi-
cant disease, despite having no coronary calcium (29).
Prevention
What should be done when a patient is found to be at
increased risk for a cardiovascular event? Recommendations
to adopt a healthy lifestyle (smoking cessation, weight
reduction for the overweight or obese, physical activity for
the sedentary) are not controversial and form the basis of the
goals for cardiovascular health recently adopted by the
American Heart Association (30). Changing these behav-
iors is notoriously difficult, however, and pharmacologic
interventions are commonly used when risk remains ele-
vated. There was disappointing news in the past year about
the use of folic acid and B vitamins to prevent heart disease:
2 more negative clinical trials were reported: 1 in 12,064
patients after MI (31) and the other in 650 patients on
hemodialysis (32).
Statin therapy is the main approach to cardiovascular risk
reduction in the population. In the past year, the JUPITER
(Justification for the Use of Statins in Prevention: An
Intervention Trial Evaluating Rosuvastatin) investigators
have published secondary analyses examining specific sub-
groups, including women (33), older patients (34), patients
with chronic kidney disease (35), and patients with different
levels of Framingham risk score (36) and high-sensitivity
CRP (37). The results of these subgroup analyses are
generally consistent with the overall trial results. The
JUPITER trial continues to generate controversy, however,
perhaps because of the large number of Americans who
might begin statin treatment on the basis of its results
(roughly 18% of the population according to a new analysis
based on ARIC data [38]). Kaul et al. (39) criticized the
JUPITER benefit-risk assessment, contending that early
stopping led to an overestimate of the benefits and an
underestimate of the risks. JUPITER reported an increased
rate of diabetes in patients assigned to statins; a subsequent
meta-analysis of 13 statin trials found a significant 9%
increase risk for developing diabetes over 4 years among
91,140 trial subjects (40).
Two analyses of lipid-lowering intervention trials sug-
gested that the conventional time-to-first-event analysis
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because second and third cardiac events are also reduced by
treatment. The IDEAL (Incremental Decrease in Endpoints
Through Aggressive Lipid Lowering) trial reported reductions
of first events by 17% (p  0.0001), second events by 24%
(p  0.0001), and third events by 19% (p  0.04) (41),
hile the PROVE IT–TIMI 22 (Pravastatin or Atorvasta-
in Evaluation and Infection Therapy–Thrombolysis In
yocardial Infarction 22) study reported that intensive
tatin therapy reduced first events by 16% and subsequent
vents by 19% (42). These analyses underscore the impor-
ance of a long-term perspective on the risks and benefits of
tatin therapy.
afety of Care
he cardiovascular safety of several commonly used drugs
as been questioned recently. Randomized trials are clearly
ccepted as the best way to assess the efficacy of drugs, but
hey have shortcomings with respect to assessing safety,
ecause trial participants are selected and closely monitored,
nd follow-up is limited, each of which minimizes adverse
ffects. A recent study suggested that the adverse effects that
o occur in trials are underreported (43), further reducing
afety signals. Consequently, observational approaches to
ssess drug safety have become more attractive.
Rosiglitazone has received particular scrutiny, prompting
n American Heart Association and American College of
ardiology Foundation science advisory statement (44) and
ecent U.S. Food and Drug Administration actions to
estrict its use. Observational comparisons of the outcomes
f patients who receive either rosiglitazone or pioglitazone
educe the problem of selection bias, because all patients
ave been chosen to receive thiazolidinedione. In a cohort of
9,736 patients age 66 years and older in Ontario who were
tarted on a thiazolidinedione, patients who received piogli-
azone had significantly lower risk than patients who re-
eived rosiglitazone for death (0.83) and heart failure (0.77),
ut not for MI (0.95) (45). An analysis of 227,571 Medicare
eneficiaries that compared pioglitazone-treated patients
ith rosiglitazone-treated patients also found a significantly
ower risk for death (0.88) and heart failure (0.80), but not
or MI (0.94) (46). In contrast, an analysis of a managed
are population of 36,628 adults (mean age 54 years) found
o differences in the rates of death, heart failure, or MI (47).
hese findings are unlikely to end the controversy over
hiazolidinediones, in light of the different results for heart
ailure and for MI.
The concomitant use of clopidogrel and proton pump
nhibitors has also generated a controversy. Recent studies that
sed clinical endpoints (rather than assays of platelet function)
uggest the pharmacodynamic interaction may not have as
reat an effect as initially feared. A study of 20,596 patients in
he Tennessee Medicaid program found no increased cardio-
ascular risk associated with proton pump inhibitor use (48).
assen et al. (49) examined 3 large cohorts of patients age 65ears and older (n 18,565) and found no increase in the risk
or death or MI (rate ratio: 1.22).
The use of cardiovascular imaging studies continues to
ise steadily, and concerns over the resulting radiation doses
ave risen as well, exacerbated by highly publicized episodes
f gross overdoses due to sophisticated CT units. Claims
ata from a large private health insurer showed that 20.5%
f the 655,613 enrollees had high doses of radiation, defined
s more than 20 mSv per year (50). Several cardiac proce-
ures were among the largest contributors to population
evel radiation exposure, with myocardial perfusion imaging
t the top of the list, as well as coronary angiography and
ercutaneous coronary intervention (PCI) (50). The poten-
ial risk of radiation exposure is difficult to project, but 1
tudy estimated that 1 in every 240 women who undergo
T coronary angiography at age 40 would develop cancer as
result (51), and another estimated 2,700 future cancers due
o the chest CT angiographic studies that were done in
007, with another 180 future cancers due to CT scans to
easure coronary calcium (52). Although there are great
ncertainties in these sorts of models (53), they nevertheless
einforce the need to minimize the radiation dose per
rocedure and to select patients appropriately for imaging
hat involves radiation exposure.
The crucial role of thrombosis in the genesis of MI, acute
oronary syndromes, and stroke (both ischemic and em-
olic) has led cardiologists to use anticoagulant and anti-
latelet drugs in many patients. Furthermore, pharmaceu-
ical companies continue to develop novel antithrombotic
rugs, in part because of the limitations of the currently
vailable treatments. There is an inherent trade-off between
educing the risk for thrombosis and increasing the risk for
leeding when using these drugs. The optimal balance
ight be achieved by proper patient selection, proper drug
osing, or both. Several studies in the past year have
ddressed this trade-off.
Warfarin anticoagulation is a mainstay of treatment for
atients with atrial fibrillation but has a narrow therapeutic
indow. Singer et al. (54) studied 13,559 patients with
onvalvular atrial fibrillation to assess the correlates of “net
linical benefit,” which they defined as the reduction in
hromboembolism due to warfarin minus the increase in
ntracranial bleeding due to warfarin. Net clinical benefit
ncreased with age and with a history of stroke or of heart
ailure; consequently, net clinical benefit increased directly
ith an increasing CHADS2 score, such that there was a
lear net benefit for a CHADS2 score of 2 points or more.
This analysis supports current consensus guidelines on
selection of patients for warfarin therapy.
A patient’s risk for bleeding should logically affect the
decision of whether he or she is given antithrombotic
therapy, but until recently, there have been few ways to
gauge that risk quantitatively. Large multicenter clinical
trials have analyzed their data on bleeding risk in an attempt
to develop clinically useful bleeding risk scores. In a 28-
month trial of clopidogrel, 3.1% of the 15,603 patients had
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gastrointestinal bleeding. Bleeding was increased by older age,
heart failure, diabetes, and the use of clopidogrel (55). The
occurrence of either bleeding, MI, or stroke each increased the
risk for death during follow-up by more than 2-fold (55). In a
trial of bivalirudin among 133,819 patients with acute coronary
syndromes, 5.1% of patients had bleeding within 30 days that
was unrelated to bypass surgery. Older age, female sex, anemia,
renal insufficiency, and prior stroke were independent predic-
tors of bleeding, along with randomized treatment to heparin
and glycoprotein IIb/IIIa inhibitor use (56). In the pooled data
from 2 trials of bivalirudin, Mehran et al. (57) developed a risk
score for bleeding based on age, sex, serum creatinine, white
blood cell count, anemia, mode of presentation, and treatment.
The score had good discrimination in the study population
(c-index 0.74), but has not been validated in an independent
cohort.
CT Coronary Angiography
The use of CT coronary angiography has been rising rapidly
with the increasing availability of new scanners with 64-slice
(and higher) capability. An expert consensus statement on
the capabilities and appropriate use of CT coronary angiog-
raphy was published recently and summarizes much of the
current state of knowledge (58), but new studies continue to
be reported that fill in knowledge gaps. Most of the early
research has compared CT angiography with invasive an-
giography, with few studies assessing the prognostic value of
CT angiography. A large cohort of 2,172 patients in Ottawa
were followed for a mean of 16 months, with a very low rate
(0.2%) of cardiac death or MI among the 591 patients with
no coronary disease and a 0.8% rate among the 866 patients
with nonobstructive disease (59). The cost-effectiveness of
CT angiography among outpatients with atypical, stable
chest pain was compared with that of several other nonin-
vasive strategies (stress electrocardiography, stress echocar-
diography, and stress myocardial perfusion imaging) in a
Monte Carlo simulation model (60). The most cost-
effective strategy was to perform CT coronary angiography
alone or in combination with stress electrocardiography,
with the results somewhat sensitive to assumptions about
the pre-test probability of disease, the patient’s sex, and the
ability of CT angiography to separate patients with 3-vessel
or left main disease from patients with 1- or 2-vessel
disease.
The approach to incidental noncardiac findings on car-
diac CT imaging has continued to be controversial. In 1
study, 41% of 966 patients who underwent cardiac CT
imaging had incidental findings (61). These findings led to
further tests, including bronchoscopy and biopsy, at a mean
cost of more than $1,000 per patient for the 80 patients with
“significant” or “indeterminate” incidental findings (61).
Similar results were reported in a series of 589 patients who
underwent CT angiography to evaluate suspected pulmo-
nary embolism (62).Health Care Utilization
PCI is one of the most common procedures performed in
the United States, so issues of cost, quality, and appropri-
ateness have come to the fore. Between 1997 and 2006, the
rate of PCI in New York rose by 6.4% per year, and PCI
was performed at more than twice the rate as in Ontario
(63). Rates of coronary bypass surgery declined steadily over
this period in both New York and Ontario (63). The
National Cardiovascular Data Registry found that a pro-
gressively greater proportion of patients with class I indica-
tions for coronary artery bypass grafting has been undergo-
ing PCI, rising from 27% in early 2001 to 37% in late 2006
(64). These trends have highlighted the issues surrounding
choices of revascularization.
It has been controversial whether PCI programs that have
low procedure volumes or at centers without cardiac surgery
have worse clinical outcomes. Data from the National
Registry of Myocardial Infarction suggest higher mortality
among patients with either STEMI (65) or non-STEMI
(66), but some of these differences were explained by lower
use of evidence-based MI therapies. In a German multi-
center registry, low-volume PCI centers had higher rates of
death and MI than high-volume PCI centers (67), even
after adjustment for clinical differences in their patient
population. O’Neill (68) argued that PCI should not be
performed at low-volume centers.
Restenosis has been reduced considerably by the wide-
spread use of drug-eluting stents, but readmissions after
PCI were surprisingly common among Medicare beneficia-
ries in 2005: 14.6% of patients were readmitted within 30
days of PCI, with 4.0% undergoing repeat revascularization
procedures (69). Rates of readmission varied widely among
hospitals, ranging from 8.9% in the lowest decile to 22.0%
in the highest decile. It is not entirely clear whether
readmission after PCI reflects quality of care, but death after
PCI is undoubtedly an important indicator. In the National
Cardiovascular Data Registry data, in-hospital mortality
after PCI was 1.27% overall in 181,775 procedures, ranging
from 0.65% for elective procedures to 4.81% for STEMI
(70). A risk model based on patient age and functional class;
history of heart failure, peripheral vascular disease, chronic
lung disease, or chronic kidney disease; the urgency of
clinical presentation; and the presence of cardiogenic shock
provided excellent risk discrimination in a prospective val-
idation sample (70).
The focus of clinicians and administrators on readmis-
sions has increased now that the data are publically reported
for heart failure and acute MI and will put outlier facilities
at risk for losing Medicare reimbursement in the near
future. However, the use of readmissions as the sole measure
of quality has been questioned by studies demonstrating that
mortality for heart failure has decreased while readmissions
rates have not (71,72) and an analysis showing an inverse
relationship between mortality and heart failure readmission
for hospitals with high readmission rates (73). Admission
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regions for patients with heart failure (74). Preventable
readmissions are thought to be due in part to poor transition
from inpatient to outpatient care. In a study of Medicare
patients with heart failure enrolled in the Get With the
Guidelines program, those facilities with earlier follow-up
(within 14 days) had lower readmission rates (75). One
study evaluated the ability of readmission rates as a measure
of quality for individual physicians in the United States (76).
With an average of 260 Medicare patients per physician
practice, no practice was large enough to reliably detect a
10% difference in 30-day readmission rates for heart failure.
Health Economics
The cost-effectiveness of management strategies to prevent
or treat various manifestations of cardiovascular disease
continues to be of interest. An economic model based on
the HPS (Heart Protection Study) suggested that treatment
with generic simvastatin may be cost effective for a wider
population in the United States than is currently recom-
mended for treatment under clinical guidelines (77). For
young (age 40 to 49 years), high-risk patients (42% 5-year
event rate), 40 mg/day of simvastatin ($1 per day) led to cost
per life-year gained of $2,500. For elderly patients (age 70
years and older) with a 12% 5-year risk, the cost per life-year
gained was $10,990. In the BARI 2D (Bypass Angioplasty
Revascularization Investigation 2 Diabetes) trial, prompt re-
vascularization with PCI for patients with diabetes and angina
was more expensive and had worse outcomes over 4 years
compared with medical therapy (78). Coronary artery bypass
grafting appeared to be cost effective compared with medical
therapy over 4 years, with a cost-effectiveness ratio at
$47,000 per life-year added, but there was substantial
uncertainty around the estimates. TRITON–TIMI 38
(Trial to Assess Improvement in Therapeutic Outcomes
by Optimizing Platelet Inhibition With Prasugrel–
Thrombolysis In Myocardial Infarction 38) found that
treatment with prasugrel was associated with reduced rates
of cardiac events compared with clopidogrel, but with an
increased risk for major bleeding (79). Both the clinical and
economic impact of these opposing outcomes has been
debated. A recent cost analysis determined that the average
total costs (including study drug) were $221 per patient
lower with prasugrel (95% confidence interval: $759 to
$299), largely because of a lower rate of rehospitalization
involving PCI. In a sensitivity analysis in which the price of
clopidogrel was assumed to be at generic drug levels ($1 per
day), prasugrel remained a cost-effective alternative ($9,700
per life-year gained).
The value of newer but more costly technologies has been
evaluated in several studies. There has been increasing
interest in improving the accuracy of warfarin dosing
through genotyping. Although expensive ($400 to $550),
genotyping has the potential to reduce complications from
inaccurate dosing for patients with atrial fibrillation. Adecision model based on published data suggests that
genotyping before warfarin initiation would be cost effective
for patients with atrial fibrillation if it reduced out-of-range
international normalized ratio values by more than 5 to 9
percentage points compared with usual care (80). Although
many patients over age 75 years receive implantable
cardioverter-defibrillator therapy to prevent sudden cardiac
death, patients in this age group have rarely been included in
randomized clinical trials. The cost-effectiveness of im-
plantable cardioverter-defibrillators in the very elderly was
assessed using a decision model derived from published
research and existing clinical trials of primary prevention of
sudden cardiac death (81). In the 5 trials evaluated, the
incremental cost-effectiveness of implantable cardioverter-
defibrillators for patients age 65 years and older ranged
between $37,000 and $138,000 per quality-adjusted life-
year added. For patients age 75 years and older, the findings
were qualitatively similar, although cost-effectiveness was
reduced in all trial populations.
The impact of self-care was assessed in an economic
analysis of the HF-ACTION (Heart Failure: A Controlled
Trial Investigating Outcomes of Exercise Training) trial,
which examined the costs of exercise training in 2,331
outpatients with medically stable heart failure (82). Exercise
did not reduce overall costs, primarily because of the extra
time costs incurred by patients in the exercise group ($5,018
per patient).
The use of 12-lead electrocardiography in preparticipation
screening of young athletes is controversial because of concerns
over the economic impact. Using a decision model based on
published data, investigators found that the benefits of screen-
ing may be worth the cost (83). They estimated that pre-
participation electrocardiographic screening saves 2.06 life-
years per 1,000 athletes at an incremental cost of $89 per
athlete (cost-effectiveness ratio $42,900 per life-year saved;
95% confidence interval: $21,200 to $71,300 per life-year
saved) compared with cardiovascular-focused history and phys-
ical examination alone. Compared with no screening, electro-
cardiography plus history and physical examination cost
$76,100 per life-year saved, whereas history and physical
examination alone were economically unattractive ($100,000
per life-year saved) compared with no screening.
Disparities
Two of the potential explanations for differences in outcome
across races or socioeconomic status include health-related
behaviors and control of treatable risk factors. An analysis of
the British Whitehall II longitudinal cohort study of 10,308
civil servants age 35 to 55 years found those with the lowest
socioeconomic position had 1.6 times higher risk of death
from all causes than those with the highest socioeconomic
position (84). The association with total mortality was
attenuated by 42% when baseline health behaviors were
included in the model and by 72% when they were added as
time-dependent covariates; for cardiovascular mortality, the
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was the strongest mediator, although diet, physical activity,
and alcohol consumption also had significant explanatory
power. Racial differences in treatable risk factors for coro-
nary disease were recently evaluated using data from
NHANES (National Health and Nutrition Examination
Survey) 1999 to 2006 (85). Control of blood pressure,
glucose, and cholesterol levels were improved since 1999 for
adults with cardiovascular disease and diabetes. However
racial and ethnic differences (worse control in nonwhites)
did not narrow significantly, although Medicare coverage
after age 65 years was associated with reductions in racial
differences.
The persistence of racial and ethnic differences in cardiovas-
cular care has been evaluated by several studies using the Get
With the Guidelines database of inpatient care from the
American Heart Association (75,86) and the PINNACLE
(Practice Innovation and Clinical Excellence) outpatient
registry of the American College of Cardiology (87). In a
study of 142,593 patients with acute MI at 443 hospitals,
defect-free care was 80.9% for whites, 79.5% for Hispanics
(adjusted odds ratio vs. whites: 1.00; 95% confidence inter-
val: 0.94 to 1.06), and 77.7% for blacks (adjusted odds ratio
vs. whites: 0.93; 95% confidence interval: 0.87 to 0.98) (75).
The significant gap in defect-free care for blacks was noted
during the first half of the study but was no longer present
in the second half of the study. A similar progressive
improvement in defect-free care in stroke was observed in
all racial and ethnic groups (86). Among 397,257 patients
admitted with ischemic stroke to 1,181 hospitals, black
patients had lower odds relative to white patients of receiv-
ing intravenous thrombolysis, deep vein thrombosis prophy-
laxis, smoking cessation, discharge antithrombotic agents,
anticoagulant agents for atrial fibrillation, and lipid therapy.
Hispanic and white patients received similar care on all 7
measures. Quality of care improved during the study in all 3
racial and ethnic groups. It is presumed that improvements
in the process of care will ultimately translate into improved
outcomes and reduced health disparities, but these effects
have not yet been demonstrated. An analysis of 14,464
outpatients from PINNACLE registry found minimal dif-
ferences by sex in 1 of 7 measures of quality for coronary
artery disease, heart failure, and atrial fibrillation (87). The
use of warfarin for women with atrial fibrillation and
CHADS scores 2 was 5% lower than for men (75% vs.
81%, p  0.03). No significant differences were noted by
race in the 7 quality measures.
Referral to cardiology specialists may influence the quality
of care and may contribute to racial differences. Disparities
by race and sex in referral to cardiology consultation was
examined in a study of 9,761 adults with coronary artery
disease or heart failure from 2000 to 2005 (88). After
adjustment for clinical characteristics, women were less
likely to receive cardiology consultations than men for either
coronary artery disease or heart failure. Women also had
15% fewer follow-up consultations than men (p  0.001).Black and Hispanic patients with heart failure had 13%
fewer follow-up consultations with cardiologists than did
white patients (p  0.01 and p  0.04, respectively). In
adjusted analyses, consultation with a cardiologist was
associated with better processes of care compared with no
consultation, particularly for women.
Although many studies have documented racial dispari-
ties in care and outcomes, few studies have examined
interventions to reduce them. One recent study evaluated
the effect of cultural competency training and performance
feedback for primary care clinicians on diabetes care for
black patients (89). Although the combination of cultural
competency training and race-stratified performance reports
increased clinician awareness of racial disparities, they did
not improve blood pressure, glycosylated hemoglobin, or
cholesterol levels among black patients.
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